Mineralys Therapeutics, Inc. (MLYS)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$667.9M
Stockholders' Equity
$550.9M
Cash & Equivalents
$138.3M
Long-Term Debt
$100,000

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Mineralys Therapeutics, Inc. reported net income of -$241.1M and total assets of $667.9M. Every figure below is taken directly from Mineralys Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$154.7M
FY2024—-$177.8M
FY2023—-$71.9M
FY2022—-$29.8M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 29, 2026on EDGAR ↗
8-KOct 19, 2026on EDGAR ↗
8-KAug 11, 2026on EDGAR ↗
10-QAug 11, 2026on EDGAR ↗
8-KJun 3, 2026on EDGAR ↗
8-KJun 3, 2026on EDGAR ↗
8-KMay 22, 2026on EDGAR ↗
10-QMay 6, 2026on EDGAR ↗
8-KMay 6, 2026on EDGAR ↗
DEF 14AApr 8, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$667.9Msource ↗
Stockholders’ Equity$550.9Msource ↗
Cash & Equivalents$138.3Msource ↗
Long-Term Debt$100,000source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$241.1Msource ↗
Operating Income-$246.0Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$221.4Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-2.85source ↗
EPS (basic)$-2.85source ↗
Shares Outstanding88.4Msource ↗
Cash from Operations-$32.6Msource ↗
Cash from Financing$243.3Msource ↗
Cash from Investing-$185.2Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
24
Net shares
-468.6K

Restatement history

Point-in-time

No material restatements detected across 86 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches MLYS’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/MLYS

MCP tool: get_sec_fundamentals ticker=MLYS

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/MLYS/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=MLYS as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/MLYS/history

MCP tool: get_fundamentals_history ticker=MLYS

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/MLYS

MCP tool: get_financial_health ticker=MLYS

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.